Conference call Interim report January to March 3, 203 Lübeck, May 2, 203
Disclaimer This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation. This presentation contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date, and have been made to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors; they entail risks and uncertainties beyond our control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this presentation. Interim financial reports as well as preliminaries are not audited. 2
Highlights Solid growth of order entry, transition into sales slow, Orders on hand strong Strong demand for Anesthesia, Monitoring, Hospital Consumables & Accessories; weaker demand in Workplace Infrastructure and Engineered Solutions Over-proportional expense growth, EBIT-margin at 7.5% Full year guidance confirmed Marketing & Sales organization operational as of January, 203 Successful start of the employee stock ownership program Update on products: Evita V300 Transportincubator GT 5400 Firefighting helmet HPS 7000 Alcotest 550 and Alcotest 6820 3
Content. Highlights Q 203 2. Financials and Outlook 3. Appendix 4
Business development Q 202 Q 203 Change % Order intake 550.9 57.3 +3.7 Orders on hand 479.9 524.0 +9.2 Net sales 529.3 Gross margin 50.0 % EBIT EBIT margin 46.8 8.8 % Income taxes.5 Tax rate 3.0 % 533.8 +0.9 50.7 % 39.8-4.9 7.5 % 0.7-6.8 32. % Earnings after income taxes 25.5 22.6 -. DVA 38.9 42. +2.3 Currency adjusted: order intake +4.5 %, orders on hand +8. %, net sales +.7 % 5
Regional split of order intake and net sales Order intake Q 203 Net sales Q 203 8% 2% 8% 9% 7% 9% 20% 34% 9% 35% Germany Rest of Europe Americas Asia/Pacific Other 8.5 96.3 4.4 97.4 44.8 vs. PY vs. PY +.6 % +2.0 % +20.0 % -2.0 % +3.9 % Germany Rest of Europe Americas Asia/Pacific Other 57.3 +4.5 % Currency adjusted Currency adjusted 99.3 87.8 02.8 0.7 42.3-2.2 % -0. % +0.6 % +4.3 % +8.2 % 533.8 +.7 % 6
Business development Medical division Q 202 Q 203 Change % Order intake 348.6 363.9 +4.4 Orders on hand 328.8 336.4 +2.3 Net sales 337.6 34.0 +.0 EBIT 28.2 27.7 -.6 EBIT margin 8.3 % 8. % DVA 4.3 33.7-5.4 Currency adjusted: order intake +5. %, orders on hand +0.9 %, net sales +2.0 % 7
Business development Safety division Q 202 Q 203 Change % Order intake 209.9 25.5 +2.7 Orders on hand 52.2 89.0 +24. Net sales 99.5 200.8 +0.6 EBIT 27.4 8.4-32.8 EBIT margin 3.7 % 9.2 % DVA 63.5 69.7 +9.7 Currency adjusted: order intake +3.4 %, orders on hand +23.9 %, net sales +.3 % 8
Key figures Q 202 Q 203 Change % Cash flow from operating activities 35.9-8.3-23.0 Investments 3.0 9.0 +45.6 Cash and cash equivalents 34. 288.9-8.0 Net financial debt 38.9 78.2-43.7 Net financial debt /EBITDA 2 0.5 0.3 Capital employed 882.4 954. +8. EBIT 2 /Capital Employed (ROCE) 24.7 % 23.4 % Net working capital 365.5 462.4 +26.5 Values at due date 2 EBITDA and accordingly EBIT of the last twelve months 9
Functional expenses Q 202 Q 203 Change % Research and development costs 46.2 48.4 +4.8 in % of net sales 8.7 % 9. % Marketing and selling expenses 4.7 49.6 +5.6 in % of net sales 26.8 % 28.0 % General administrative expenses 30.3 34. +2.5 in % of net sales 5.7 % 6.4 % Expenses Total 26.9 23.9 +7.0 in % of net sales 4.0 % 43.4 % 0
Outlook and mid-term perspective 202 203 Midterm 208 Net sales +5.2 % (currency adjusted +2.5 %) 2.0 % - 4.0 % CAGR > 4 % EBIT margin 9.7 % 8.0 % - 0.0 % 0.0 % - 2.0 % Gross Margin 49.2 % 48.5 % - 49.5 % Cash flow conversion 77 % of EBIT 70 % - 85 % of EBIT Equity ratio 34.6 % 35 % 38 %
Appendix. Executive Board 2. Financial calendar 3. Contact 2
Executive Board Executive Board of Drägerwerk Verwaltungs AG Stefan Dräger CEO Dr. Herbert Fehrecke CTO Gert-Hartwig Lescow CFO Toni Schrofner COO 3
Financial calendar March 2, 202 Accounts press conference, Hamburg Analysts meeting, Frankfurt May 2, 202 Report for the first three months 203 Conference call, Lübeck May 3, 202 Annual shareholders meeting, Lübeck August, 202 Report for the first six months 203 Conference call, Lübeck October 3, 202 Report for the first nine months 203 Conference call, Lübeck 4
Contact Melanie Kamann Corporate Communications Thomas Fischler Investor Relations Drägerwerk AG & Co. KGaA Drägerwerk AG & Co. KGaA Moislinger Allee 53 55 Moislinger Allee 53 55 23558 Lübeck, Germany 23558 Lübeck, Germany Tel +49 45 882-3998 Tel +49 45 882-2685 Fax +49 45 882-3944 Fax +49 45 882-3296 Mobile +49 70 855852 Mobile +49 5 2245295 melanie.kamann@draeger.com www.draeger.com thomas.fischler@draeger.com www.draeger.com 5
6 Diversity at Dräger